Answers are grounded in this paper and cite their sources.
INTRODUCTION: Children with chronic hepatitis B (CHB) may face decades of infection before developing advanced liver disease. Although antiviral options have expanded, pediatric management remains challenging because of age-dependent treatment eligibility, limited long-term evidence, and uncertainty regarding functional cure. AREAS COVERED: This narrative review examines treatment indications, international guidelines, and the efficacy and safety of interferon-based therapy and nucleos(t)ide analogues in children and adolescents. International guidelines were prioritized, supplemented by PubMed and Cochrane Library searches through September 2026 without a lower publication-date limit. We discuss treatment withdrawal and developmental safety, including management during immunosuppression, considerations for special populations and transition to adult care. Emerging therapies are assessed with particular attention to the limits of applying adult results to children. EXPERT OPINION: In our view, earlier treatment deserves studies, but younger age alone is insufficient grounds for intervention. Favorable responses in selected childhood cohorts do not establish that treating all children with high viremia improves lifelong outcomes. Bepirovirsen offers a concrete route toward finite therapy by reducing HBV transcripts, yet adult efficacy cannot establish pediatric benefit. Over the next five years, adolescent trials should determine whether such treatment could achieve sustained HBsAg loss after withdrawal without unacceptable toxicity. Until then, effective NA suppression remains a clinically valuable option, even when cure is not achieved.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: